Why the ResMed share price is printing record highs

Sleep therapy giant RESMED/IDR UNRESTR (ASX: RMD) has a bulletproof record of revenue growth. Should you buy, hold, or sell ResMed shares?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investing in blue-chip Australian shares has been a bit of a mixed picture for Australian investors over the past few years. Leading companies in the mining sector such as Rio Tinto Limited (ASX: RIO) and BHP Group Ltd (ASX: BHP) have hit 52-week highs on the back of rising commodity prices, while the big banks like Commonwealth Bank of Australia (ASX: CBA) have been touching 52-week lows on the back of multiple problems. 

All of the aforementioned businesses tend to have some cyclicality about them, but a less cyclical business hitting record highs today is sleep therapy giant RESMED/IDR UNRESTR (ASX: RMD). It has a bulletproof record of revenue growth thanks mainly to its dominant position treating sleep apnea in large global addressable markets.

As a result, its shares have nearly tripled in the past five years and ResMed's CEO, Mick Farrell, is fond of repeating the mantra that the company is only in the first mile of its race to run a marathon.

It is now attempting to move deeper into the digital- or cloud-connected health space, in part as this provides better margins and also because the rich datasets generated by connected healthcare could demonstrate how the company's preventative treatments for common sleep disorders actually save public healthcare funders (i.e. governments) on patient costs further down the line. 

The scrip traded on the ASX at $16.70 today represents an FX-adjusted, 1/10th interest on its primary listing on the NYSE. Therefore, as the Australian dollar falls, quarterly dividend payments and profits for Australian investors rise as the company reports and pays dividends in US dollars. 

Based on its NYSE share price of US$116.89, the shares trade on 30x analysts' consensus estimates for earnings per share of US$3.89 in FY20.

Motley Fool contributor Tom Richardson owns shares of ResMed Inc. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Senior man wearing glasses and a leather jacket works on his laptop in a cafe.
Broker Notes

Should I still swap my CSL for CBA shares or has the market corrected?

The two stocks have travelled opposite directions this month.

Read more »

Man with rocket wings which have flames coming out of them.
Resources Shares

Why Macquarie expects this ASX All Ords copper stock could surge 38%

With costs coming in below expectations, this ASX All Ords copper stock could rocket higher over the coming months.

Read more »

woman holding 'hiring' sign in shop
Broker Notes

Can you guess whether Macquarie prefers REA Group, CAR Group or SEEK shares?

Which ASX online classifieds business offers the best investment opportunity today?

Read more »

An ASX shares broker analysing a chart tracking the A2 Milk share price
Share Market News

Are these two struggling ASX materials shares undervalued?

Are these buy-low candidates?

Read more »

Female miner smiling in front of a mining vehicle as the Pilbara Minerals share price rises
Broker Notes

Expert says this ASX All Ords small cap mining stock could rocket 38%

Big upside ahead?

Read more »

Happy man working on his laptop.
Share Market News

5 things to watch on the ASX 200 on Wednesday

It looks set to be another good session for Aussie investors tdaoy.

Read more »

Two laughing young women hold shopping bags and ride an escalator up to another level in a Scentre Group shopping centre.
Broker Notes

3 ASX consumer sector shares to buy in July: expert

A leading expert has named its top 3 picks.

Read more »